Ovarian Cancer: Risk Factors, Treatment, and Prognosis
This paper provides a thorough clinical overview of ovarian cancer, examining the disease from a nursing perspective. It explores the etiology and risk factors associated with ovarian cancer, including genetic mutations, age, and hormone replacement therapy, before reviewing incidence and prevalence statistics. The paper details the pathophysiology of tumor progression, characteristic signs and symptoms, and standard diagnostic tests. Treatment approaches — including surgery, chemotherapy, and emerging targeted therapies — are discussed alongside evidence-based precision medicine and pharmacogenetic considerations. The paper concludes with a review of staging, survival rates by stage and cancer type, and nursing care plan considerations designed to support patient empowerment and informed decision-making.
- Introduction: Overview of ovarian cancer and paper scope
- Etiology and Risk Factors: DNA mutation process and key risk factors
- Incidence and Prevalence: Diagnosis rates, mortality statistics, and trends
- Pathophysiology: Tumor progression, gene mutations, and cancer types
- Signs, Symptoms, and Diagnostic Tests: Clinical presentation and diagnostic procedures
- Treatment and Pharmacogenetic Considerations: Surgery, chemotherapy, targeted therapy, and precision medicine
- Prognosis and Nursing Care Plan: Survival rates by stage and patient-centered nursing care
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Covers the full clinical arc from etiology through nursing care, giving the paper a logical, encyclopedic structure well suited to a healthcare audience.
- Integrates specific statistical data (incidence rates, survival percentages by stage) that grounds abstract claims in measurable evidence.
- Connects pharmacogenetic research findings — such as the role of ABCB1 and CYP2C8 genotypes in paclitaxel metabolism — to practical treatment decisions, demonstrating upper-level clinical reasoning.
- Balances clinical detail with patient-centered considerations, particularly in the nursing care plan section, which addresses health literacy and emotional support.
Key academic technique demonstrated
The paper demonstrates effective synthesis of multiple source types — clinical guidelines, epidemiological statistics, pharmacogenetic studies, and pathophysiology research — to build a unified argument for early detection and precision treatment. Rather than summarizing each source in isolation, the author weaves them together to support specific claims, such as the role of targeted therapy in managing relapse.
Structure breakdown
The paper follows a systematic clinical report structure: introduction → etiology/risk factors → epidemiology → pathophysiology → clinical presentation and diagnosis → treatment → evidence-based practice → staging and prognosis → nursing care. Each section builds on the previous, moving from foundational biology to practical clinical application. The conclusion reinforces the central argument that early detection and targeted therapy are the most critical factors in improving survival outcomes.
Introduction
Ovarian cancer begins in the ovaries — of which there are two in each woman, each almond-sized — where estrogen, progesterone, and testosterone are produced and where the body's ova are generated and released. While the cancer originates in the ovaries, it is not confined to them: it is typically not identified until it has spread into the woman's abdomen or pelvis, at which point it becomes much more difficult to treat. That is why screening for and identifying ovarian cancer at an early stage is so vital to saving a woman's life. This paper discusses the risk factors and etiology of ovarian cancer, incidence and prevalence rates, pathophysiology, signs and symptoms, diagnostic tests, treatment, evidence-based practice precision medicine and pharmacogenetic considerations, prognosis, and nursing considerations including a care plan.
Etiology and Risk Factors
The specific etiology of ovarian cancer is unknown (Mayo Clinic, 2019). However, it is generally understood that cancer proceeds in stages. First, there is a mutation in a cell's DNA, which causes the cell to multiply abnormally. This is what produces a tumor. Every cell has a natural lifespan, but cancerous cells continue to survive where normal cells would not. They become invasive and spread to other parts of the body.
Risk factors for ovarian cancer include: (1) advanced age, (2) inherited genes prone to cancer, (3) family history, (4) estrogen hormone replacement therapy, and (5) beginning menstruation at an early age or starting menopause at a late age (Mayo Clinic, 2019). While there is no clear way of preventing ovarian cancer, Mayo Clinic (2019) advises discussing possible preventive methods with one's doctor.
Incidence and Prevalence
According to the American Cancer Society (2019), approximately 22,530 new women are diagnosed with ovarian cancer each year. Nearly 14,000 women will die from ovarian cancer in that same year. It is the fifth leading cause of cancer-related deaths among women and accounts for a greater percentage of mortality than all other cancers related to the female reproductive system. There is currently about a 1 in 78 lifetime chance of developing ovarian cancer and a 1 in 110 chance of dying from it — placing the likelihood of death by ovarian cancer at just under 1% for women (American Cancer Society, 2019).
Half of all women diagnosed with ovarian cancer are over the age of 63. The cancer is most often found in white women rather than in black women. Diagnoses have been declining and trending downward for the past two decades, which is a positive sign that early intervention is occurring (American Cancer Society, 2019). Early screenings play a significant role in this downward trend, as do lifestyle choices: though the precise causes of ovarian cancer remain unknown, healthy eating habits, regular exercise, and similar behaviors generally contribute to better overall health outcomes.
Conclusion
Ovarian cancer is one of the leading causes of cancer-related death among women. It most commonly affects older women in their 60s, though it has been known to affect younger patients as well. While the cancer is treatable, long-term survival rates are not favorable: beyond five years, the odds of survival decline rapidly. This is why targeted therapy has received increasing attention from researchers in recent years. Greater focus on preventing ovarian cancer, treating it effectively, and reducing recurrence will improve prognosis over time. Currently, the most effective treatment methods are surgery and chemotherapy; however, not all patients will be willing to sacrifice their reproductive organs. This reality underscores the critical importance of early detection through frequent screening. When cancer is identified in Stage 1, survival odds reach the 90th percentile — a compelling argument for making routine screening both accessible and normalized.
References
American Cancer Society. (2019). Key statistics for ovarian cancer. Retrieved from https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html
Furuya, M. (2012). Ovarian cancer stroma: Pathophysiology and the roles in cancer development. Cancers, 4(3), 701–724.
Green, H., Söderkvist, P., Rosenberg, P., Mirghani, R. A., Rymark, P., Lundqvist, E. Å., & Peterson, C. (2009). Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic & Clinical Pharmacology & Toxicology, 104(2), 130–137.
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014). Ovarian cancer. Lancet, 384(9951), 1376–1388.
Mayo Clinic. (2019). Ovarian cancer. Retrieved from https://www.mayoclinic.org/diseases-conditions/ovarian-cancer/symptoms-causes/syc-20375941
World Health Organization. (2018). Cancer. Retrieved from https://www.who.int/news-room/fact-sheets/detail/cancer
Yap, T. A., Carden, C. P., & Kaye, S. B. (2009). Beyond chemotherapy: Targeted therapies in ovarian cancer. Nature Reviews Cancer, 9(3), 167–181.
Create your account
Always verify citation format against your institution’s current style guide requirements.